WallStSmart

Edwards Lifesciences Corp (EW)vsWipro Limited ADR (WIT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Wipro Limited ADR generates 14880% more annual revenue ($908.92B vs $6.07B). EW leads profitability with a 17.7% profit margin vs 14.6%. EW appears more attractively valued with a PEG of 2.14. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

WIT

Buy

53

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 7.3Quality: 7.3
Piotroski: 5/9Altman Z: 3.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$81.69

$69.38 premium

UndervaluedFair: $12.31Overvalued
WITSignificantly Overvalued (-151.6%)

Margin of Safety

-151.6%

Fair Value

$0.95

Current Price

$2.10

$1.15 premium

UndervaluedFair: $0.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

WIT4 strengths · Avg: 9.0/10
Free Cash FlowQuality
$37.93B10/10

Generating 37.9B in free cash flow

Altman Z-ScoreHealth
3.5210/10

Safe zone — low bankruptcy risk

P/E RatioValuation
15.4x8/10

Attractively priced relative to earnings

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

WIT2 concerns · Avg: 3.0/10
PEG RatioValuation
2.474/10

Expensive relative to growth rate

EPS GrowthGrowth
-7.2%2/10

Earnings declined 7.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : WIT

The strongest argument for WIT centers on Free Cash Flow, Altman Z-Score, P/E Ratio.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.6x leaves little room for execution misses.

Bear Case : WIT

The primary concerns for WIT are PEG Ratio, EPS Growth.

Key Dynamics to Monitor

EW profiles as a mature stock while WIT is a value play — different risk/reward profiles.

EW carries more volatility with a beta of 0.93 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

WIT generates stronger free cash flow (37.9B), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 53/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Wipro Limited ADR

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Wipro Limited is a global information technology (IT), consulting and business process services company. The company is headquartered in Bengaluru, India.

Want to dig deeper into these stocks?